Definium Therapeutics Inc. shares gained ground in morning trading, rising 3.0% to $45.79 after Stifel published a bullish analyst note late Monday. The firm doubled its price target on the company to $60 from $30 while keeping a Buy rating, pointing to stronger-than-expected Phase 3 clinical data for the company’s lead candidate, DT120, in major depressive disorder.
Stifel interpreted the MDD readout as a meaningful reduction in program risk for DT120 and concluded the commercial opportunity is materially larger than it had previously assumed. In its note, the broker increased its modeled probability of approval to 80% for both the MDD and generalized anxiety disorder indications and projected combined peak revenues in excess of $4 billion. Stifel likened the potential revenue pathway to that of Spravato and identified the next major catalyst as topline results from the first Phase 3 study in GAD.
The move in Definium shares occurred against a difficult market backdrop. The S&P 500 was down 0.5%, the Dow Jones Industrial Average fell 1.0%, and the Nasdaq slipped 0.4% during the same session, indicating DFTX was outperforming the broader market on the strength of company-specific news.
Stifel’s upgrade added to existing Wall Street support that had already been cited by investors. Canaccord previously issued a Buy rating with a $58 target and Needham set a $50 target; both firms anchored their views to the positive Phase 3 Emerge MDD readout announced in late June.
The timing of Stifel’s revised target - arriving after the prior trading session had closed and feeding into the next morning’s market open - served as the immediate trigger for the stock’s advance. The note layered fresh institutional conviction on top of an already supportive clinical narrative and helped Definium trade within striking distance of its 52-week high of $49.20.
What to watch next
- Topline data from the first Phase 3 generalized anxiety disorder study, identified by Stifel as the next key inflection point.
- Market reaction in the context of broader equity weakness, since the stock’s move has been driven primarily by firm-specific catalysts rather than general market strength.